BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ortiz MV, Roberts SS, Glade Bender J, Shukla N, Wexler LH. Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Front Oncol 2019;9:108. [PMID: 30873384 DOI: 10.3389/fonc.2019.00108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Xing C, Jiang S, Yu K, Dai S, Kong H, Jin Y, Shan Y, Yang W, Wang Z, Xiao J, Wang H, Wang W, Li Z, Shi K. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report. Front Immunol 2022;13:963031. [DOI: 10.3389/fimmu.2022.963031] [Reference Citation Analysis]
2 Sibuh BZ, Gahtori R, Al-Dayan N, Pant K, Far BF, Malik AA, Gupta AK, Sadhu S, Dohare S, Gupta PK. Emerging trends in immunotoxin targeting cancer stem cells. Toxicol In Vitro 2022;83:105417. [PMID: 35718257 DOI: 10.1016/j.tiv.2022.105417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bu W, Zhu M, Li S, Liu H, Liu X. Novel GPC3 Gene Mutation in Simpson-Golabi-Behmel Syndrome with Endocrine Anomalies: A Case Report. Balkan Journal of Medical Genetics 2021;24:95-8. [DOI: 10.2478/bjmg-2021-0024] [Reference Citation Analysis]
4 Hong B, Dong R. Research advances in the targeted therapy and immunotherapy of Wilms tumor: a narrative review. Transl Cancer Res 2021;10:1559-67. [PMID: 35116480 DOI: 10.21037/tcr-20-3302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lu J, Jin M, Zhou X, Chen X, Shao Y, Jiang X. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes. APMIS 2021. [PMID: 34862662 DOI: 10.1111/apm.13196] [Reference Citation Analysis]
6 Haydar D, Ibañez-Vega J, Krenciute G. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges. Front Oncol 2021;11:718030. [PMID: 34760690 DOI: 10.3389/fonc.2021.718030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Nie JH, Yang T, Li H, Ye HS, Zhong GQ, Li TT, Zhang C, Huang WH, Xiao J, Li Z, He JL, Du BL, Zhang Y, Liu J. Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. J Bone Oncol 2021;30:100391. [PMID: 34611509 DOI: 10.1016/j.jbo.2021.100391] [Reference Citation Analysis]
8 Palmisani F, Kovar H, Kager L, Amann G, Metzelder M, Bergmann M. Systematic review of the immunological landscape of Wilms tumors. Mol Ther Oncolytics 2021;22:454-67. [PMID: 34553032 DOI: 10.1016/j.omto.2021.06.016] [Reference Citation Analysis]
9 Hu M, Li M, Huang H, Lu C. Isolated cancer stem cells from human liver cancer: morphological and functional characteristics in primary culture. Clin Transl Oncol 2021. [PMID: 34169442 DOI: 10.1007/s12094-021-02667-w] [Reference Citation Analysis]
10 Chen Z, Dong R. Advances in the conventional clinical treatment for hepatoblastoma and therapeutic innovation. World Jnl Ped Surgery 2021;4:e000220. [DOI: 10.1136/wjps-2020-000220] [Reference Citation Analysis]
11 Tzanakakis GN, Giatagana EM, Berdiaki A, Spyridaki I, Hida K, Neagu M, Tsatsakis AM, Nikitovic D. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis. Cancers (Basel) 2021;13:2478. [PMID: 34069554 DOI: 10.3390/cancers13102478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
12 Wang JY, Wang XK, Zhu GZ, Zhou X, Yao J, Ma XP, Wang B, Peng T. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma. BMC Cancer 2021;21:462. [PMID: 33902495 DOI: 10.1186/s12885-021-08104-z] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Rodakowska E, Walczak-Drzewiecka A, Borowiec M, Gorzkiewicz M, Grzesik J, Ratajewski M, Rozanski M, Dastych J, Ginalski K, Rychlewski L. Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells. Oncol Lett 2021;21:222. [PMID: 33613711 DOI: 10.3892/ol.2021.12483] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Yu L, Yang X, Huang N, Wu M, Sun H, He Q, Lang Q, Zou X, Liu Z, Wang J, Ge L. Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors. Invest New Drugs 2021;39:615-26. [PMID: 33215325 DOI: 10.1007/s10637-020-01033-x] [Reference Citation Analysis]
15 Vyas M, Zhang X. Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:591-610. [DOI: 10.1016/j.cld.2020.07.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
16 Shen G, Shen H, Zhang J, Yan Q, Liu H. DNA methylation in Hepatoblastoma-a literature review. Ital J Pediatr 2020;46:113. [PMID: 32758256 DOI: 10.1186/s13052-020-00877-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lanzi C, Cassinelli G. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities. Biochemical Pharmacology 2020;178:114084. [DOI: 10.1016/j.bcp.2020.114084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
18 Zhang J, Yi J, Zhou P. Development of bispecific antibodies in China: overview and prospects. Antib Ther 2020;3:126-45. [PMID: 33928227 DOI: 10.1093/abt/tbaa011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
19 Gulberti S, Mao X, Bui C, Fournel-gigleux S. The role of heparan sulfate maturation in cancer: A focus on the 3O-sulfation and the enigmatic 3O-sulfotransferases (HS3STs). Seminars in Cancer Biology 2020;62:68-85. [DOI: 10.1016/j.semcancer.2019.10.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Khazamipour N, Al-Nakouzi N, Oo HZ, Ørum-Madsen M, Steino A, Sorensen PH, Daugaard M. Oncofetal Chondroitin Sulfate: A Putative Therapeutic Target in Adult and Pediatric Solid Tumors. Cells 2020;9:E818. [PMID: 32231047 DOI: 10.3390/cells9040818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Wiedemeyer K, Köbel M, Koelkebeck H, Xiao Z, Vashisht K. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. Hum Pathol 2020;98:56-63. [PMID: 32017945 DOI: 10.1016/j.humpath.2020.01.002] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Lv Y, Lin SY, Hu FF, Ye Z, Zhang Q, Wang Y, Guo AY. Landscape of cancer diagnostic biomarkers from specifically expressed genes. Brief Bioinform 2020;21:2175-84. [PMID: 31814027 DOI: 10.1093/bib/bbz131] [Cited by in Crossref: 13] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
23 Xavier PLP, Cordeiro YG, Alexandre PA, Pires PRL, Saranholi BH, Silva ER, Müller S, Fukumasu H. An epigenetic screening determines BET proteins as targets to suppress self-renewal and tumorigenicity in canine mammary cancer cells. Sci Rep 2019;9:17363. [PMID: 31758045 DOI: 10.1038/s41598-019-53915-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sha YL, Liu S, Yan WW, Dong B. Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma. Biosci Rep 2019;39:BSR20192466. [PMID: 31511432 DOI: 10.1042/BSR20192466] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
25 Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 38] [Article Influence: 8.7] [Reference Citation Analysis]
26 Kolluri A, Ho M. The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer. Front Oncol 2019;9:708. [PMID: 31428581 DOI: 10.3389/fonc.2019.00708] [Cited by in Crossref: 24] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]